ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

The Alliance for Clinical Trials in Oncology initiated a randomized phase III clinical trial called RECIPROCAL to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

January 09, 2026

Vol.52 No.1

In Brief

Northwell, START unveil $5.7M early-phase clinical trial center

Northwell Health and START Center for Cancer Research have unveiled a $5.7M, 10,000 square foot early-phase cancer clinical trial center that aims to provide better access to treatments for cancer patients in New York and Long Island.

December 19, 2025

Vol.51 No.46

In Brief

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Khalil Choucair has joined the thoracic oncology and phase I clinical trials multidisciplinary teams as a medical oncologist at Karamos Cancer Institute.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal.

December 19, 2025

Vol.51 No.46

Drugs & Targets

EC approval of Minjuvi in relapsed or refractory follicular lymphoma

The European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grade 1-3a) after at least one line of systemic therapy.

December 19, 2025

Vol.51 No.46

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

Northwell, START unveil $5.7M early-phase clinical trial center

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

EC approval of Minjuvi in relapsed or refractory follicular lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login